An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence.

Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
Brian F McBrideC Michael White

Abstract

Intravenous magnesium reduces the QTc interval of patients receiving ibutilide. Whether oral magnesium can reduce the QTc interval associated with oral sotalol and dofetilide is not known. This study was undertaken to evaluate the impact of oral magnesium on the QTc interval and whether an inherent intracellular magnesium deficiency exists among patients with arrhythmias. Participants receiving sotalol or dofetilide for atrial or ventricular arrhythmias were randomized to receive magnesium l-lactate (504 mg elemental magnesium daily, Niche Pharmaceuticals, Roanoke, TX) or placebo for 48 hours. A 12-lead electrocardiogram (ECG) was obtained at baseline, 3 hours, and 51 hours after dosing to correspond to the Tmax after oral ingestion. The QTc interval was measured from the ECGs and compared between groups. Intracellular magnesium concentrations were determined by energy-dispersive x-ray analysis at baseline and 51 hours after dosing (Intracellular Diagnostics, Inc., Foster City, CA). The QTc interval reductions from baseline were greater in the magnesium group than placebo at 3 and 51 hours (P = 0.015 and P < 0.001, respectively). Sixty-three percent of patients (regardless of experimental group) had baseline intracellular magne...Continue Reading

References

Apr 16, 1998·Journal of Electrocardiology·C AntzelevitchS Sicouri
Mar 28, 2001·Progress in Cardiovascular Diseases·M M BednarJ N Ruskin
Dec 6, 2002·The New England Journal of Medicine·D G WyseUNKNOWN Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators
Mar 12, 2003·Pharmacotherapy·Michael F CaronC Michael White
Dec 5, 2003·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·James S KalusC Michael White
Oct 7, 2004·Journal of the American College of Nutrition·Anushka P MichailovaAndrew D McCulloch

❮ Previous
Next ❯

Citations

Sep 26, 2008·Current Treatment Options in Cardiovascular Medicine·Gerald Serwer
Jan 31, 2015·Indian Heart Journal·Abhishek Jaiswal, Seth Goldbarg
Feb 10, 2009·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·D Almoznino-SarafianO Gorelik
Jun 5, 2013·Pacing and Clinical Electrophysiology : PACE·Harsha V GangaJeffrey Kluger
Jun 26, 2010·Pharmacotherapy·Edward C LiBrian F McBride
Aug 21, 2010·The American Journal of Cardiology·Sotirios PatsilinakosDimitrios Babalis
May 24, 2015·Cardiac Electrophysiology Clinics·Michael G Fradley, Javid Moslehi
Oct 22, 2016·European Heart Journal. Cardiovascular Pharmacotherapy·William L Baker
Apr 2, 2009·The Annals of Pharmacotherapy·William L BakerCraig I Coleman
Jan 24, 2016·Journal of the American Heart Association·Brenda C T KieboomEwout J Hoorn
Apr 12, 2021·The American Journal of Emergency Medicine·Megan HofferAli Pourmand
Sep 1, 2017·The American Journal of Emergency Medicine·Ali PourmandMohammed Almulhim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.